Skip to main content
. 2022 Mar 25;14:17588359221085333. doi: 10.1177/17588359221085333

Table 5.

Pathological response in patients of the study cohort with different PD-L1 TPS.

Study cohort Pathological response
PD-L1 TPS (NA 3) n MPR pCR
⩾50% 27 20 (74%) 16 (59%)
1–49% 25 16 (64%) 12 (48%)
0% 4 2 (50%) 1 (25%)

MPR, major pathological response; pCR, complete pathological response, PD-L1, programmed-death ligand 1; TPS, tumour-proportion score.